Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration

Authors not listed

Oxford BioMedica · 2011

Abstract

The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Anonymous. (2011). A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration. <em>Oxford BioMedica</em>. https://clinicaltrials.gov/study/NCT01301443
Vancouver
Anonymous. A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration. Oxford BioMedica. 2011.
BibTeX
@misc{anon2011APhase, title = {A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration}, author = {Anonymous}, journal = {Oxford BioMedica}, year = {2011}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings